Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04907838

Enrollment

Registered

2021-06-01

Start date

2018-05-01

Completion date

2021-07-30

Last updated

2021-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Brief summary

This study evaluates the role of endothelin in insulin stimulated vasodilation and glucose uptake. The subjects will complete an hyperinsulinemic euglycemic clamp with and without blockade of the endothelin receptors.

Interventions

DRUGInsulin clamp

Continous infusion insulin + glucose

DRUGBQ123

Continuous infusion of Insulin + glucose + BQ123

DRUGBQ123 + BQ788

Continous infusion of insulin + glucose + BQ123 + BQ788

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Type 2 diabetes OR healthy control (no type 2 diabetes) * BMI\<32

Exclusion criteria

* heart disease * pregnancy or birth within 3 month * smoking * Kidney disease * beta-blockers * insulin treatment (for type 2 diabetics)

Design outcomes

Primary

Measure	Time frame	Description
Glucose infusion rate	3.5 hours	Glucose infusion rate required to maintain euglycemia during insulin clamp with and without endothelin blockade
Leg blood flow	3.5 hours	Effect of endothelin receptor blockade on leg blood flow (ultrasound Doppler) during insulin clamp with and without endothelin blockade

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026